Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Conditions

Chronic Lymphocytic Leukemia (CLL)

Keywords

Chronic Lymphocytic Leukemia (CLL), Cancer, Leukemia, venetoclax, rituximab, obinutuzumab, ABT-199, venclexta, venclyxto

Brief summary

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

Ilaria Romano, Alessio Bruscaggin, Georg Stüssi, Simone Bocchetta, Katia Pini et al. (16 authors)

Blood2025-11-03

10.1182/blood-2025-3901

Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.

Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, Hülsenbeck J, Famulla K, Nösslinger T, Rossi D.

2024-02-292 citations

10.1007/s00277-024-05638-7

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

Katia Pini, Alessio Bruscaggin, Maria Cristina Pirosa, Gabriela Forestieri, Joyce Marques de Almeida et al. (15 authors)

Blood2023-11-02

10.1182/blood-2023-180509

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

\- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.

Exclusion criteria

\- None

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Achieving Best Overall Response Rate (ORR)	Up to 12 months	ORR is defined as the percentage of participants achieving partial response (PR) and complete response with incomplete regeneration of bone marrow (CRi) and complete response (CR) according to physician's assessment to therapy with venetoclax.

Countries

Austria, Germany, Switzerland

Contacts

CONTACTJohannes Huelsenbeck

johannes.huelsenbeck@abbvie.com+49 611-1720-3036

CONTACTStefan Lorenz

stefan.lorenz@abbvie.com

STUDY_DIRECTORABBVIE INC.

AbbVie

Outcome results